Related Experiment Video
Updated: Jun 18, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
CELF2 Is a Tumor Suppressor That Modulates SLC7A11 and Promotes Ferroptosis in Stomach Adenocarcinoma
Shoucai Zhang1,2, Shichao Liu1,2, Zeyu Zhang1,2
1Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, P.R. China.
Abstract:
Stomach adenocarcinoma is among the most prevalent malignant gastrointestinal tumors worldwide. Ferroptosis, a relatively new form of programmed cell death, has garnered significant attention for its role in cancer molecular mechanisms and therapeutic strategies. Therefore, it is particularly important to explore the mechanism of key molecules in ferroptosis in stomach adenocarcinoma. In our study, CUGBP Elav-like family member 2 (CELF2) was identified as being lowly expressed in stomach adenocarcinoma tumor tissues at both the mRNA and protein levels. Next, CELF2 effectively inhibited the growth and migration of stomach adenocarcinoma cells both in vitro and in vivo. RNA sequencing (RNA-seq) analysis of AGSCELF2 and AGSNC cells showed that the functions of differentially expressed genes were enriched in the glutathione metabolism and ferroptosis pathways. CELF2 increased the levels of key ferroptosis markers, including reactive oxygen species, malondialdehyde, Fe2+, and 4-hydroxynonenal, while reducing glutathione levels. Furthermore, CELF2 enhanced the susceptibility of stomach adenocarcinoma tumor cells to ferroptosis. Interestingly, the expression levels of CELF2 and solute carrier family 7 member 11 (SLC7A11) were negatively correlated in RNA-seq data and The Cancer Genome Atlas database. RNA immunoprecipitation and RNA pull-down assays confirmed the interaction between CELF2 and SLC7A11. Overexpression (OE) of SLC7A11 reversed the effects of CELF2 on stomach adenocarcinoma growth and ferroptosis levels. Moreover, the ferroptosis inhibitor ferrostatin-1 effectively rescued the inhibitory effect of CELF2 OE on the proliferation of tumor cells. CELF2 is a tumor suppressor that promotes the level and susceptibility of ferroptosis in stomach adenocarcinoma cells by targeting SLC7A11.
Implications:
This study offers valuable molecular insights for the development of ferroptosis-targeted therapies for stomach adenocarcinoma.
Insights
CUGBP Elav-like family member 1 (CELF2) acts as a tumor suppressor in stomach adenocarcinoma (STAD) by promoting ferroptosis. CELF2 targets SLC7A11, enhancing ferroptosis susceptibility and inhibiting STAD growth.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- Stomach adenocarcinoma (STAD) is a major global gastrointestinal malignancy.
- Ferroptosis, a distinct form of programmed cell death, is increasingly recognized for its role in cancer.
- Understanding ferroptosis regulators in STAD is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the role of CUGBP Elav-like family member 1 (CELF2) in stomach adenocarcinoma (STAD).
- To elucidate the mechanism by which CELF2 influences ferroptosis in STAD.
- To explore the potential of CELF2 as a therapeutic target for STAD.
Main Methods:
- Analysis of CELF2 expression in STAD tissues (mRNA and protein).
- In vitro and in vivo experiments assessing CELF2's effect on STAD cell growth and migration.
- RNA sequencing (RNA-seq) to identify CELF2-regulated pathways, including glutathione metabolism and ferroptosis.
- Biochemical assays to measure ferroptosis markers (ROS, MDA, Fe²⁺, 4-HNE, GSH).
- RNA immunoprecipitation (RIP) and RNA pull-down assays to confirm CELF2-SLC7A11 interaction.
Main Results:
- CELF2 expression was significantly downregulated in STAD tissues.
- CELF2 overexpression inhibited STAD cell proliferation and migration in vitro and in vivo.
- CELF2 promoted ferroptosis by increasing ROS, MDA, Fe²⁺, and 4-HNE levels while decreasing GSH.
- CELF2 directly interacted with Solute carrier family 7 member 11 (SLC7A11), a key regulator of ferroptosis.
- SLC7A11 overexpression counteracted the anti-tumor and ferroptosis-inducing effects of CELF2.
- Ferrostatin-1 treatment rescued CELF2-induced inhibition of STAD cell proliferation.
Conclusions:
- CELF2 functions as a tumor suppressor in STAD.
- CELF2 promotes ferroptosis in STAD cells by targeting SLC7A11.
- CELF2 enhances STAD cell susceptibility to ferroptosis.
- Targeting CELF2 and the ferroptosis pathway presents a promising therapeutic avenue for STAD.
Related Concept Videos
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
